drugset / Trial / NCT01820143

Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety

NCT01820143

Phase 1 Completed 40 enrolled Il-Yang Pharm. Co., Ltd.
RandomizedCrossoverOpen-label

Summary

The objectives of this study were (a) to evaluate the pharmacokinetics and to evaluate and compare the pharmacodynamics of ilaprazole and esomeprazole following a single dose (Day 1) and once daily (QD) administration for 5 consecutive days each of 10-mg, 20-mg, and 40-mg ilaprazole tablets and 40-mg esomeprazole tablets; (b) to evaluate the safety of 10-mg, 20-mg, and 40-mg ilaprazole tablets following QD oral administration for 5 consecutive days; and (c) to characterize the plasma gastrin concentration profile on Day 1 and Day 5 following QD oral administration of 10-mg, 20-mg, and 40-mg ilaprazole and 40-mg esomeprazole tablets for 5 consecutive days.

Timeline

Start
2005-02
Primary completion
2005-04
Completion
2005-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Esomeprazole Small molecule 40 mg Oral
Subject Ilaprazole Small molecule 10 mg Oral
Subject Ilaprazole Small molecule 20 mg Oral
Subject Ilaprazole Small molecule 40 mg Oral

Indications

No indication recorded.